用NKG2A/C开关受体准HLA-E过度表达的癌症
Michelle Sætersmoen1, Ivan S Kotchetkov2, Lamberto Torralba-Raga1
1Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Med (New York, N.Y.)
|October 18, 2024
概括
工程 A/C 开关受体向人类白细胞抗原 (HLA) -E 在质母细胞瘤细胞上,增强 T 细胞和 NK 细胞的抗瘤活性. 这种方法对HLA-E过度表达的瘤有望,具有有利的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 细胞疗法细胞疗法
背景情况:
- 人类白细胞抗原 (HLA) -E在质母细胞瘤等固体瘤中过度表达,通过NKG2A受体抑制CD8+ T细胞和NK细胞.
- 这种HLA-E/NKG2A轴与PD-L1一起抑制瘤微环境中的抗瘤免疫反应.
研究的目的:
- 设计一种新型的仿制受体 (A/C开关) 来克服HLA-E介导的免疫抑制.
- 评估A/C切换工程T和NK细胞对HLA-E表达瘤细胞的疗效.
主要方法:
- 设计了一种嵌合式A/C开关受体,将NKG2A外域和NKG2C内域信号结合起来.
- 评估了A/C切换转化NK和T细胞对不同HLA-E表达的瘤细胞的细胞毒性功能.
- 在使用质母细胞瘤异种移植模型评估体内疗效.
主要成果:
- 经过A/C切换转换的NK和T细胞对中高HLA-E表达瘤细胞表现出优异的特异性细胞毒性.
- 在A/C切换表达的人类T细胞在质母细胞外移植模型中显示出增强的抗瘤活性.
- 确定了治疗窗口,最大限度地降低了外瘤毒性,因为正常细胞仍然不敏感.
结论:
- A/C切换受体有效地准HLA-E过度表达的瘤细胞,克服NKG2A/HLA-E检查点.
- 这种工程受体为HLA-E过度表达瘤提供了一个有前途的治疗策略,具有良好的安全性.
关键词:
在CAR T细胞中,在HLA-E的基础上,HLA-E在 NK 细胞中,NK 细胞是 NK 细胞.NKG2受体家族中的NKG2受体家族.临床前研究 临床前研究癌症免疫疗法免疫疗法质母细胞瘤 (glioblastoma) 是一种更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
702
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.4K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
